These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 27230836)

  • 1. [Pathophysiology of primary hyperparathyroidism].
    Kaji H
    Clin Calcium; 2016 Jun; 26(6):815-20. PubMed ID: 27230836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular pathogenesis of primary hyperparathyroidism.
    Arnold A; Shattuck TM; Mallya SM; Krebs LJ; Costa J; Gallagher J; Wild Y; Saucier K
    J Bone Miner Res; 2002 Nov; 17 Suppl 2():N30-6. PubMed ID: 12412775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic defects associated with familial and sporadic hyperparathyroidism.
    Hendy GN; Cole DE
    Front Horm Res; 2013; 41():149-65. PubMed ID: 23652676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular profiling in primary hyperparathyroidism.
    Segiet OA; Deska M; Michalski M; Gawrychowski J; Wojnicz R
    Head Neck; 2015 Feb; 37(2):299-307. PubMed ID: 24595969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Concept, etiology and epidemiology of primary hyperparathyroidism].
    Martínez Díaz-Guerra G; Hawkins Carranza F
    Endocrinol Nutr; 2009 Apr; 56 Suppl 1():2-7. PubMed ID: 19627754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. One hundred and seven family members with the rearranged during transfection V804M proto-oncogene mutation presenting with simultaneous medullary and papillary thyroid carcinomas, rare primary hyperparathyroidism, and no pheochromocytomas: is this a new syndrome--MEN 2C?
    Shifrin AL; Xenachis C; Fay A; Matulewicz TJ; Kuo YH; Vernick JJ
    Surgery; 2009 Dec; 146(6):998-1005. PubMed ID: 19958926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular pathogenesis of primary hyperparathyroidism.
    Cetani F; Pardi E; Borsari S; Marcocci C
    J Endocrinol Invest; 2011 Jul; 34(7 Suppl):35-9. PubMed ID: 21985978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary hyperparathyroidism caused by parathyroid-targeted overexpression of cyclin D1 in transgenic mice.
    Imanishi Y; Hosokawa Y; Yoshimoto K; Schipani E; Mallya S; Papanikolaou A; Kifor O; Tokura T; Sablosky M; Ledgard F; Gronowicz G; Wang TC; Schmidt EV; Hall C; Brown EM; Bronson R; Arnold A
    J Clin Invest; 2001 May; 107(9):1093-102. PubMed ID: 11342573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MEN1 intragenic deletions may represent the most prevalent somatic event in sporadic primary hyperparathyroidism.
    Alvelos MI; Vinagre J; Fonseca E; Barbosa E; Teixeira-Gomes J; Sobrinho-Simões M; Soares P
    Eur J Endocrinol; 2013 Feb; 168(2):119-28. PubMed ID: 23093699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary hyperparathyroidism as the first clinical manifestation of multiple endocrine neoplasia type 2A in a 5-year-old child.
    Magalhães PK; Antonini SR; de Paula FJ; de Freitas LC; Maciel LM
    Thyroid; 2011 May; 21(5):547-50. PubMed ID: 21449769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Type I membrane klotho expression is decreased and inversely correlated to serum calcium in primary hyperparathyroidism.
    Björklund P; Krajisnik T; Akerström G; Westin G; Larsson TE
    J Clin Endocrinol Metab; 2008 Oct; 93(10):4152-7. PubMed ID: 18682507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary hyperparathyroidism--what the nephrologist should know--an update.
    Raue F; Frank-Raue K
    Nephrol Dial Transplant; 2007 Mar; 22(3):696-9. PubMed ID: 17138574
    [No Abstract]   [Full Text] [Related]  

  • 13. The RET p.G533C mutation confers predisposition to multiple endocrine neoplasia type 2A in a Brazilian kindred and is able to induce a malignant phenotype in vitro and in vivo.
    Oliveira MN; Hemerly JP; Bastos AU; Tamanaha R; Latini FR; Camacho CP; Impellizzeri A; Maciel RM; Cerutti JM
    Thyroid; 2011 Sep; 21(9):975-85. PubMed ID: 21834681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary hyperparathyroidism as the leading symptom in a patient with a Y791F RET mutation.
    Vierhapper H; Rondot S; Schulze E; Wagner L; Hanslik S; Niederle B; Bieglmayer C; Kaserer K; Baumgartner-Parzer S
    Thyroid; 2005 Nov; 15(11):1303-8. PubMed ID: 16356097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cinacalcet HCl suppresses Cyclin D1 oncogene-derived parathyroid cell proliferation in a murine model for primary hyperparathyroidism.
    Imanishi Y; Kawata T; Kenko T; Wada M; Nagano N; Miki T; Arnold A; Inaba M
    Calcif Tissue Int; 2011 Jul; 89(1):29-35. PubMed ID: 21541686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor suppressor LKB1 inhibits activation of signal transducer and activator of transcription 3 (STAT3) by thyroid oncogenic tyrosine kinase rearranged in transformation (RET)/papillary thyroid carcinoma (PTC).
    Kim DW; Chung HK; Park KC; Hwang JH; Jo YS; Chung J; Kalvakolanu DV; Resta N; Shong M
    Mol Endocrinol; 2007 Dec; 21(12):3039-49. PubMed ID: 17761947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abnormal parathyroid cell proliferation precedes biochemical abnormalities in a mouse model of primary hyperparathyroidism.
    Mallya SM; Gallagher JJ; Wild YK; Kifor O; Costa-Guda J; Saucier K; Brown EM; Arnold A
    Mol Endocrinol; 2005 Oct; 19(10):2603-9. PubMed ID: 15928311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma.
    Schulten HJ; Al-Maghrabi J; Al-Ghamdi K; Salama S; Al-Muhayawi S; Chaudhary A; Hamour O; Abuzenadah A; Gari M; Al-Qahtani M
    Anticancer Res; 2011 Dec; 31(12):4179-83. PubMed ID: 22199277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of MEN2A-derived RET in maintenance and proliferation of medullary thyroid carcinoma.
    Drosten M; Hilken G; Böckmann M; Rödicker F; Mise N; Cranston AN; Dahmen U; Ponder BA; Pützer BM
    J Natl Cancer Inst; 2004 Aug; 96(16):1231-9. PubMed ID: 15316058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutational analysis of the vitamin D receptor does not support its candidacy as a tumor suppressor gene in parathyroid adenomas.
    Samander EH; Arnold A
    J Clin Endocrinol Metab; 2006 Dec; 91(12):5019-21. PubMed ID: 17003089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.